SciMar is a New Jersey-based woman-owned company with deep roots in healthcare and technology. SciMar’s proprietary AI-powered technology, the DV Platform™ modernizes drug development’s antiquated manual processes using cloud and AI to help pharma get life-changing therapies to market faster. SciMar was founded by CEO, Donna Conroy, MS whose 25-year career – first as a microbiologist, then in pharma, and later as a vendor all served to bring innovative therapies to market. It was these experiences that allowed her to identify and name this problem in drug development and design a system to address it. Development Velocity™ (DV™) is the speed a pharma company moves a therapy through the development process and into the market. The DV Platform was born from SciMar’s pharma, technology, and business experience. The platform was built from the ground up for pharma, not another retrofitted solution.
What is the problem?
When a promising therapy emerges from discovery, the clock starts ticking on its trajectory from the lab to the market, and beyond. While pharma invests millions in AI to discover new drugs, the same antiquated processes are used to develop promising candidates. Clinical trials are the most familiar element of development, yet they represent only a portion of the cross-functional workload. Twelve cross-functional teams work simultaneously to complete over 300 critical, interdependent tasks that move a therapy towards commercialization. Most development teams utilize outdated workflows and analytical processes to complete tremendous volumes of work. This creates bottlenecks of inefficiency that disrupt the time-sensitive and costly journey to commercialization. The result is the development process loses momentum (slowing DV) due to extended timelines and escalating budgets. Drug development requires a holistic platform to replace legacy processes and meet the needs of broader development teams.
What is their solution?
Peak DV™ is attainable by modernizing antiquated processes with SciMar’s AI-powered, cloud-based DV Platform™. This comprehensive platform, built for pharma, helps accelerate therapies through the development process and into the market faster. The first-ever comprehensive The DV Platform™ (DVP™) helps pharma accelerate therapies through the development process to get to market faster. Faster development journeys are less expensive and provide a competitive advantage. The DCP achieves these goals by: • Replacing manual legacy processes • Analyzing and utilizing disease-specific data rapidly • Improving cross-functional collaboration by aligning workflow The DV platform accelerates! By significantly reducing the 5–7-year development cycle with time efficiencies, the SDE saves companies up to a quarter billion dollars in R&D costs per year. Most importantly, speed to market enables better health outcomes because life-changing and life-saving therapies are available to patients faster
